TP53 mutations in endometrial cancers relation to PTEN gene defects

International Journal of Gynecological Cancer

Volumn 20, Issue 2, 2010, Pages 196-202

  Janiec Jankowska, Aneta ^a   Konopka, Bozena ^a   Goluda, Cyprian ^b   Najmoaa, Urszula ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Endometrial carcinoma; Mutations; PTEN; TP53

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; DNA ISOLATION; ENDOMETRIUM CANCER; FEMALE; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEX DIFFERENCE; SINGLE STRAND CONFORMATION POLYMORPHISM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PTEN PHOSPHOHYDROLASE;

EID: 77951934001     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c83675     Document Type: Article

References (34)

1. Didkowska J, Wojciechowska U, Tarkowski W, et al. Nowotwory zaovliwe w Polsce w 2003 roku. Warszawa, Centrum Onkologii-Instytut im. M. Skaodowskiej-Curie; 2005.
2. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
3. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
4. Risinger JI, Hayers K, Maxwell GL, et al. PTEN mutations in endometrial cancer is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4:3005-3010.
5. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991;164:15-21.
6. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46:26-32.
7. Konopka B, Janiec-Jankowska A, Paszko Z, et al. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. J Cancer Res Clin Oncol. 2004;130:114-121.
8. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
9. Soyoola EO, Pattillo RA. PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors. Am J Obstet Gynecol. 2003;188:33-36.
10. Tang Y, Eng Ch. PTEN autoregulates its expression by stabilization of p53 in phosphatase-independent manner. Cancer Res. 2006;66:736-742.
11. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317-325.
12. Oki E, Tokunaga E, Nakamura T, et al. Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Lett. 2005;227:33-38.
13. Creasman WT. Revision in classification by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1992;167:857-858.
14. Scully RE, Bonfiglio TA, Kurman RJ. Histological Typing of Female Genital Tract Tumors, in WHO: International Histological Typing of Tumors. New York: Springer; 1994:14-31.
15. Risinger JI, Hayers AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;37:4736-4738.
16. Buchman VL, Chumakov PM, Ninkina NN, et al. Avariation in the structure of the protein-coding region of the human p53 gene. Gene. 1988;70:245-252.
17. Sakuragi S, Salah-Eldin A, Watari H, et al. Bax, bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol. 2002;86:288-296.
18. Macwhinnie N, Monaghan H. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer. 2004;14:938-946.
19. Koul A, Willen R, Bendahl PO, et al. Distinct sets of gene alterations endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002;94:2369-2379.
20. Ørbo A, Kaino T, Arnes M, et al. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Gynecol Oncol. 2004;95:82-88.
21. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22:9030-9040.
22. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21:313-316.
23. De Witte HH, Foekens JA, Lennerstrand J. Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer. 1996;69:125-133.
24. Su JD, Mayo LD, Donner BD, et al. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003;63:3585-3592.
25. Li AG, Piluso LG, Cai X, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23:575-587.
26. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
27. Elmasry K, Gayther SA. Genetic mutations in gynaecological cancers. Rev Gynaecol Perinat Pract. 2006;6:115-125.
28. Kim HJ, Song ES, Hwang TS. Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection. Eur J Obstet Gynecol Reprod Biol. 2001;98:213-218.
29. Mateu MG, Fersht AR. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerisation status of tumour suppressor p53 tetramerization domain. EMBO J. 1998;17:2748-2758.
30. Powell B, Soong R, Iacopetta B. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res. 2000;6:443-449.
31. Lea IA, Jackson MA, Li X, et al. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis. 2007;28:1851-1858.
32. Kushi AA, Lim P, Aquino-Parsons C, et al. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol. 2002;15:365-371.
33. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002;16:984-993.
34. Inaba F, Kawamat H, Teramoto T, et al. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep. 2005;13:17-24.